Registry for newly diagnosed peripheral T-cell lymphoma patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This is an observational registry that collects real-world information about people newly diagnosed with peripheral T-cell or certain NK-cell lymphomas. It does not test a new drug, but it helps researchers understand patterns of disease and care, which can guide future studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 or older).
- Your lymphoma diagnosis must be new and previously untreated.
- Your diagnosis should be one of several specific types of T-cell or NK-cell lymphoma.
- You need an adequate tissue biopsy, and the tissue must be available for expert review.
- You must be able to provide consent and agree to follow-up information being updated for at least 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This study is looking at how peripheral T-cell lymphoma (PTCL) behaves and responds to treatment in real-world settings. It includes patients diagnosed over many years to better understand the disease and improve care.
This trial uses a genetic test on your lymphoma tissue to help choose your treatment. It may help personalize therapy for people with newly diagnosed peripheral T-cell lymphoma and see how well the approach works and is tolerated.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
This registry tracks people with non-Hodgkin lymphoma who are starting a new line of systemic therapy. It collects information to better understand how treatments work in real life, and optionally asks you to fill out surveys about your symptoms and quality of life.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.